|
Brain Imaging in Elderly People and Individuals with Alzheimer's Disease Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Brain Imaging in Elderly People and Individuals with Alzheimer's Disease conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Brain Imaging in Elderly People and Individuals with Alzheimer's Disease Clinical research trials and Brain Imaging in Elderly People and Individuals with Alzheimer's Disease health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Brain Imaging in Elderly People and Individuals with Alzheimer's Disease. Brain Imaging in Elderly People and Individuals with Alzheimer's Disease Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Brain Imaging in Elderly People and Individuals with Alzheimer's Disease clinical trial. Participants oftentimes recieve the most expert healthcare available for their Brain Imaging in Elderly People and Individuals with Alzheimer's Disease condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Brain Imaging in Elderly People and Individuals with Alzheimer's Disease  Brain Imaging in Elderly People and Individuals with Alzheimer's Disease
Brain Imaging in Elderly People and Individuals with Alzheimer's Disease
For Condition: Alzheimer's Disease,Healthy
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to use brain imaging technology to study the effects of aging and Alzheimer's Disease (AD) on a specific type of brain receptor. The brain is made up of cells called neurons. The neurons communicate with one another and secrete chemicals called neurotransmitters. The neurotransmitters bind to specific sites on other neurons called receptors. Acetylcholine (ACh) is a neurotransmitter that binds to ACh receptors. In both aging and AD, the number of neurons that secrete ACh decreases and the function of some ACh receptors changes. This study will use positron emission tomography (PET) scans of the brain to study the effects of age and AD on muscarinic type 2 [M2], a type of ACh receptor. Participants in this study will be injected with a radioactive tracer (ligand [F-18] FP-TZTP) which binds to [M2] receptors. Participants will then undergo a PET scan in order for the density and function of [M2] receptors to be studied.
Details: The Geriatric Psychiatry Branch (GPB) of the National Institute of Mental Health (NIMH) proposes to study the effect of aging and Alzheimer's Disease (AD) on muscarinic type 2 (M2) receptor density and function using the ligand [F-18] FP-TZTP. M2 receptors are primarily autoreceptors found on acetylcholine (ACh) neurons, and are lost along with ACh neurons in aging and AD, particularly in the cerebral cortex. As we near completion of the study of the young versus the old, we would like to add a few more healthy subjects to achieve better gender balance, continue the accrual of Alzheimer's patients and expand the Protocol to include its natural scientific progression. Quantification of M2 receptors with a single FP-TZTP scan as we are currently performing with 99-M-0073 provides a measure of the number of cholinergic receptors in the brain, but not their capacity to release acetylcholine into the synapse. To test this capacity requires a second TZTP scan and the use of an agent that alters acetylcholine concentrations in the synapse. Non-human primate studies performed here (1) have found PET scans with FP-TZTP to be sensitive to changes in acetylcholine synapse concentrations, as a result of competition, in response to the adminstration of the acetylinesterase inhibitor physostigmine. We would like to use physostigmine in all groups; young, older normal, and Alzheimer's patients to infer differences in capacity to release acetylcholine.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Healthy males and females between 20-100 years old and volunteers with AD. AD volunteers must meet the NINCDS-ADRDA criteria for possible, probable, or definite AD. All subjects will be required to be off all prescription medications which could effect the PET scan, such as medications with anticholinergic effects, for two weeks to one month prior to the PET scan, and off psychotropic medication for one month. Subjects will be cautioned not to consume alcohol, marijuana, or psychotropic drugs while on the study, nor to smoke, use caffeinated beverages, or take over-the-counter medications such as cold medications (ie: Benadryl, Sudafed) for at least 12 hours prior to the PET scan. EXCLUSION CRITERIA: Patients withe significant cardiovascular disease, history of alcoholism, significant head trauma, uncontrolled hypertension, diabetes, bleeding disorders or other medical conditions which would make it medically unsafe to perform any part of the PET scan or would confound data analysis. Subjects with evidence of significant chronic disease to be accepted into the healthy control group. Subjects must not be pregnant.
Total Enrollment: 150
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Robert Cohen 3014026985
Additional Information:
Study ID Numbers: 990073; 99-M-0073
Study Start Date: April 2, 1999
Record last reviewed: April 4, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001917
Other Healthy Studies:
1. Study of an Investigational Drug for the treatment of Alzheimer's Disease
2. Nefiracetam in the Treatment of Alzheimer's Disease
3. Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer’s Disease
4. PET Scan of Brain Metabolism in Relation to Age and Disease
5. Effects of an Anti-Inflammatory Drug in Alzheimer's Disease
Related Studies:
Other Healthy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Brain Imaging in Elderly People and Individuals with Alzheimer's Disease
|
|
|
|
|
|
|
|
